Company Active LTD

Company profile

Cumulus Neuroscience Limited

Cumulus Neuroscience

Cumulus Neuroscience Limited is a UK company with status active founded in 2015 based in Northern Ireland.

CRN
NI628481
Founded
2015
Age
11

Overview

Legal name
CUMULUS NEUROSCIENCE LIMITED
Region
Northern Ireland
Registered address
UNIT 5, CONCOURSE BUILDING 3
QUEENS ROAD
BELFAST
NORTHERN IRELAND
BT3 9DT
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Cumulus Neuroscience Limited
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

26 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

12 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

20 Sep
2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQzNjY4MTkwM2FkaXF6a2N4

Published 20 Sep 2024 11:14

20 Sep
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzNjY5OTYwOWFkaXF6a2N4

Published 20 Sep 2024 01:54

05 Jan
2015

Incorporated

Inception

Company registered at Companies House

Public funding

6 awards
First funded
2017
Funded years
2017, 2019, 2020, 2021, 2023, 2024
Age at first award
1 years

Projects

2024 Collaborative R&D Lead participant

Accelerating Alzheimer’s Diagnosis (AccelADx) to Enable Precision Clinical Trial Patient Stratification and Clinical Care using Neurophsyiological Biomarkers and AI

1 May 2024 to 31 Jul 2026

Awarded
£1,197,564
Total cost £1,197,564

Alzheimer's dementia (AD) is a devastating disease for patients and their families, directly affecting almost 60M people today, expected to reach 139M by 2050\. It is a global problem, that needs a global solution. But the disease appears very gradually and can be hard to detect early. This means people can miss the opportunity to fully benefit from newer...

2023 Collaborative R&D Lead participant

Optimising Blood Biomarker Accuracy for Clinical Trials and Healthcare using Artificial Intelligence and Digital Biomarkers

1 Dec 2023 to 30 Nov 2024

Awarded
£987,781
Total cost £987,781

**The need for accurate early diagnosis** The 2022 World Alzheimer Report estimates that 55 million people globally are living with dementia, projected to rise to 139 million by 2050\. Early diagnosis tools are desperately needed, with diagnosis typically occurring late in the disease process and misdiagnosis common due to the overlap of cognitive symptom...

2021 Collaborative R&D Lead participant

Cumulus NeuroScience: Real-World Technology to Accelerate Clinical Trials in Dementia

1 Mar 2021 to 30 Jun 2023

Awarded
£1,824,330
Total cost £2,606,185

It is estimated that more than one million people in the UK will have dementia by 2025, with one in three born in 2015 projected to develop it in their lifetimes (ARUK, www.dementiastatistics.org). Clinical trials in this field are typically long, drug development costs are extremely high, and success rates for development of dementia treatments are excee...

2020 Feasibility Studies Lead participant

Accelerating Value to an EEG-based solution for Remote Trials, during COVID-19 (AVERT COVID-19)

1 Jun 2020 to 30 Nov 2020

Awarded
£49,603
Total cost £49,603

The global crisis caused by the COVID-19 pandemic has had a profound and widespread effect on healthcare. Priorities have necessarily shifted, and resources have been diverted to assist with the crisis. For many thousands of patients enrolled in ongoing or planned clinical trials, it is vital to maintain safety but also minimise, where possible, disruptio...

2019 Collaborative R&D Lead participant

ANTONA-MH: Accelerating New Therapies with Objective Neurophysiological Assessment for Mental Health

1 Sep 2019 to 30 Nov 2021

Awarded
£636,777
Total cost £909,681

Mental health conditions like depression and schizophrenia affect millions of citizens in the UK, and have consequences for their quality of life, as well as families and wider communities. One reason that mental health conditions are difficult to treat is that it is hard to diagnose them precisely, or to know when a possible treatment is working, as that...

2017 Collaborative R&D Lead participant

In-home screening of cognitive ageing to enable improved patient outcomes

1 Jan 2017 to 31 Mar 2018

Awarded
£329,994
Total cost £471,420

A novel neuroscience platform is proposed that allows anyone to directly measure and track their cognitive health in just a few minutes a day from the comfort of their home. This low cost approach will make quantitative, objective cognitive health tracking accessible to all and transform our understanding of brain health including how lifestyle, age, and ...

Product types

Collaborative R&D Feasibility Studies